Cambridge, MA, July 12, 2021 — Takeda Pharmaceutical Company Limited (“Takeda”) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., are providing an update regarding a short-term supply interruption that will impact some patients who are receiving NATPARA® (parathyroid hormone) for Injection through the Special Use Program (SUP). The supply interruption is limited to NATPARA 75-mcg and does not impact any other NATPARA doses within the SUP.

Due to a shipment delay of NATPARA 75-mcg, patients for whom Takeda has an alternate prescription on file will be shipped their alternate prescription beginning Tuesday, July 13 to maintain supply continuity for those patients. Other patients are not impacted at this time. Patients temporarily receiving alternate prescriptions will revert back to their original prescription (NATPARA 75-mcg) the week of July 19, when shipments of NATPARA 75-mcg resume. Patients with alternate prescriptions that are not equivalent to 75-mcg we will require a new prescription to return to the original 75-mcg dose. If a new prescription is needed, based on the patient’s physician’s medical judgement, the prescribing physician should contact Takeda OnePath® as soon as possible.

Patients who require assistance may contact their Takeda OnePath® Patient Support Manager at 1-866-888-0660, Monday through Friday 8:30AM – 8:00PM ET.

Takeda deeply regrets that we are anticipating a short-term supply interruption of NATPARA 75-mcg and we are working with urgency to maintain supply continuity for impacted SUP patients.

###